Acumen Pharmaceuticals (ABOS) Non-Current Assets (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 6 years of Non-Current Assets data on file, last reported at $535000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 98.92% year-over-year to $535000.0; the trailing twelve-month figure through Mar 2026 stood at $34.7 million (down 81.9% YoY), and the FY2025 full-year result was $581000.0, down 99.04% from the prior year.
• Non-Current Assets declined to $535000.0 in Q1 2026, from $581000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $67.8 million in Q3 2023 to a low of $535000.0 in Q1 2026.
• A 5-year average of $31.8 million and a median of $27.9 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 9526.85% in 2023 and tumbled 99.04% in 2025, its largest moves.
• Tracing ABOS's Non-Current Assets over 5 years: stood at $16.3 million in 2022, then soared by 290.64% to $63.5 million in 2023, then declined by 4.45% to $60.7 million in 2024, then sank by 99.04% to $581000.0 in 2025, then retreated by 7.92% to $535000.0 in 2026.
• Business Quant data shows ABOS's Non-Current Assets at $535000.0 in Q1 2026, $581000.0 in Q4 2025, and $10.1 million in Q3 2025.